Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 5,477 matching trials from the live ClinicalTrials.gov search.
Conditions
Unspecified Adult Solid Tumor
Interventions
bevacizumab, cyclophosphamide, imatinib
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
Interventions
Berzosertib, Biopsy Specimen, Biospecimen Collection, Computed Tomography, Irinotecan Hydrochloride
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
Conditions
Adenocarcinoma, Neoplasms
Interventions
Torisel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 21 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 8 more
Conditions
Tumor, Solid
Interventions
BDB001 (EIK1001), Pembrolizumab
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Sarasota, Florida • Morristown, New Jersey • Nashville, Tennessee + 1 more
Conditions
Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Quality of Life Forms
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
8 Years to 20 Years
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
17
States / cities
Duarte, California • Oakland, California • Denver, Colorado + 14 more
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide lipid matrix
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more
Conditions
Solid Tumors
Interventions
ASP5878
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
20 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Orange, California • New York, New York • Cleveland, Ohio + 3 more
Conditions
Advanced Solid Tumors
Interventions
[14C]linifanib, ABT-869, linifanib
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Advanced Refractory Solid Tumors
Interventions
P7170
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
glutamine, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Immune Checkpoint Inhibitor
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
Interventions
Fragmin, placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions
Cytology Specimen Collection Procedure, Medical Chart Review
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
75,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
246
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more
Conditions
Malignant Solid Tumor
Interventions
GEN1055, Pembrolizumab, Standard Chemotherapy
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Solid Tumors
Interventions
BAY1436032
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Houston, Texas • Charlottesville, Virginia
Conditions
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Interventions
favezelimab/pembrolizumab, pembrolizumab, lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
Conditions
Malignancy, Cancer, Hematological Malignancies, Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor
Interventions
Commercial CAR-T, Investigational CAR-T
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Interventions
TNG260, Pembrolizumab
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Santa Monica, California • Denver, Colorado • Sarasota, Florida + 10 more
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Interview, Text Message-Based Navigation Intervention
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Pancreatic Cancer
Interventions
biopsy with 19 gauge needle, biopsy with 25 gauge needle
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
19 Years to 89 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
4
States / cities
Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more
Completed Phase 4 Interventional Results available

Durvalumab Long-Term Safety and Efficacy Study

NCT04078152
Conditions
Solid Tumor
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Fullerton, California • Washington D.C., District of Columbia • Augusta, Georgia + 9 more
Conditions
Neoplasms
Interventions
ADH-1, melphalan
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 4 more